Keywords
selectins
endothelial dysfunction
chronic inflammation
metabolic syndrome
How to Cite
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and represents a serious medical and social problem of modern healthcare. The growth of obesity, type 2 diabetes, metabolic syndrome, and insulin resistance contributes to the increase in the frequency of NAFLD worldwide. Modern concepts of the disease pathogenesis indicate a multifactorial nature of its development, including lipid metabolism disorders, chronic inflammation, oxidative stress, endothelial dysfunction, and immune disorders.References
Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence and outcomes // Hepatology. — 2016. — Vol. 64, №1. — P. 73–84.
Byrne C.D., Targher G. NAFLD: a multisystem disease // Journal of Hepatology. — 2015. — Vol. 62, №1. — P. S47–S64.
Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis // Gastroenterology. — 2010. — Vol. 139, №6. — P. 1801–1802.
Sookoian S., Pirola C.J. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile // Alimentary Pharmacology & Therapeutics. — 2017. — Vol. 46, №1. — P. 85–95.
Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease // Journal of Hepatology. — 2016. — Vol. 65, №3. — P. 589–600.
Kansas G.S. Selectins and their ligands: current concepts and controversies // Blood. — 1996. — Vol. 88, №9. — P. 3259–3287.
Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated // Nature Reviews Immunology. — 2007. — Vol. 7, №9. — P. 678–689.
Simons N., Isaacs A., Koek G.H., Kuc S., Schaper N.C., Brouwers M.C.G.J. Soluble E-selectin and NAFLD: a biomarker of disease severity // Liver International. — 2020. — Vol. 40, №5. — P. 1079–1088.
Koroy P.V., Smirnova E.N., Volkova N.I. Selectins in metabolic liver diseases and endothelial dysfunction // Therapy. — 2021. — Vol. 7, №2. — P. 45–52.
